Newron Pharmaceuticals

Contact
newron.com
+39026103461

Newron Pharmaceuticals SpA

via Ludovico Ariosto 21
20091 Bresso
Italy
+39026103461
newron.com
Contact
Profile Products News
Contact

About Newron Pharmaceuticals

We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX stock exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS), including pain.

Read more about Newron Pharmaceuticals
Facts about Newron Pharmaceuticals
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Newron Pharmaceuticals

Product portfolio

Show all

News about Newron Pharmaceuticals

Newron Pharmaceuticals

12-May-2017 | research and development

Newron Receives EUR11.3m Milestone Payments

US Approval of Xadago for the treatment of Parkinson’s disease

Read news
Newron Pharmaceuticals

15-Jul-2015 | research and development

Rett syndrome: Newron Receives FDA Orphan Drug Designation for Sarizotan

Newron Pharmaceuticals S.p.A. announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Newron’s New Chemical Entity ...

Read news
Newron Pharmaceuticals

24-Oct-2011 | research and development

Merck Returns Rights for Safinamide to Newron

Merck KGaA announced that it has decided to return all rights for safinamide to Newron Pharmaceuticals S.p.A. Merck had acquired exclusive worldwide rights ...

Read news
Newron Pharmaceuticals

29-Sep-2011 | business & finance

Biotie to Acquire Newron Creating a Leading European Biopharmaceutical Company Focused on Central Nervous System Drug Development

Biotie Therapies Corp. and Newron Pharmaceuticals S.p.A. announced that they have signed an agreement for Biotie to acquire Newron in a transaction valued ...

Read news
Newron Pharmaceuticals

01-Jul-2011 | research and development

Merck Completes Patient Enrollment in MOTION, a Phase III Pivotal Clinical Trial of Safinamide in Early Parkinson’s Disease

Study will evaluate safety and efficacy of safinamide as add-on to dopamine agonist therapy in early Parkinson’s disease

Read news
Newron Pharmaceuticals

05-Nov-2010 | research and development

Merck KGaA: Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson’s Disease

Merck KGaA and its partner Newron Pharmaceuticals S.p.A. announced the top-line results of an 18-month, double-blind, placebo-controlled extension study ( ...

Read news
Newron Pharmaceuticals

24-Feb-2005 | business & finance

Newron Pharmaceuticals Raises EUR 30 Million

Newron Pharmaceuticals SpA, a research and development company focused on novel CNS therapies, announced the raising of EUR 30 million (fully committed), ...

Read news
Newron Pharmaceuticals

12-Jan-2005 | science

Newron Pharmaceuticals Successfully Completes Pilot Study of Safinamide in Restless Legs Syndrome

Newron Pharmaceuticals SpA, a research and development company focused on novel CNS therapies, announced that treatment with its investigational new drug ...

Read news
Show more news about Newron Pharmaceuticals

Here you will find Newron Pharmaceuticals SpA